ABSTRACT
A systematic review of cell models of acquired drug resistance not involving genetic manipulation showed that 80% of cell models had an inverse resistance relationship between cisplatin and paclitaxel [1] . Here we systematically review genetically modified cell lines in which the inverse cisplatin/paclitaxel resistance phenotype has resulted. This will form a short list of genes which may play a role in the mechanism of the inverse resistance relationship as well as potential markers for monitoring the development of resistance in the clinical treatment of cancer. The literature search revealed 91 genetically modified cell lines which report toxicity or viability/apoptosis data for cisplatin and paclitaxel relative to their parental cell lines. This resulted in 26 genes being associated with the inverse cisplatin/paclitaxel phenotype. The gene with the highest number of genetically modified cell lines associated with the inverse resistance relationship was BRCA1 and this gene is discussed in detail with reference to chemotherapy response in cell lines and in the clinical treatment of breast, ovarian and lung cancer. Other genes associated with the inverse resistance phenotype included dihydrodiol dehydrogenase (DDH) and P-glycoprotein. Genes which caused cross resistance or cross sensitivity between cisplatin and paclitaxel were also examined, the majority of these genes were apoptosis associated genes which may be useful for predicting cross resistance. We propose that BRCA1 should be the first of a panel of cellular markers to predict the inverse cisplatin/paclitaxel resistance phenotype.
INTRODUCTION
The chemotherapeutic drugs cisplatin and paclitaxel are used in the treatment of many solid tumours. Cisplatin binds to the DNA strand, hindering both DNA replication and RNA translation and eventually triggering apoptosis. Paclitaxel causes cytotoxicity by binding to and stabilising polymerised microtubules. Initial responsiveness to cisplatin therapy is high, however the majority of patients ultimately relapse with resistant disease. Mechanisms of cisplatin resistance characterised in resistant cell models include; decreased cellular accumulation of drug, increased levels of glutathione, increased levels of DNA repair and increased anti-apoptotic activity [2] . Similarly, many patients will relapse with disease resistant to paclitaxel therapy. Paclitaxel resistance can be mediated by P-glycoprotein export decreasing the cellular accumulation [3] . Other mechanisms of paclitaxel resistance include altered expression or post-translational modification of β-tubulin, the target of paclitaxel, or other microtubule regulatory proteins. Any alteration in microtubule dynamics, paclitaxel binding sites or signalling pathways up or downstream of microtubule polymerisation can potentially mediate paclitaxel resistance [4] .
Due to their differing mechanisms of action cisplatin and paclitaxel are often combined in cancer therapy. However, work in cell lines suggests that alternating between the two classes of drugs may be beneficial. In a recent systematic review article we examined the cross resistance relationship between cisplatin and paclitaxel in cell models of acquired drug resistance [1] . The vast majority of cell models had an inverse resistance relationship between cisplatin and paclitaxel. When cisplatin resistance occurs cell lines are likely to have no change in resistance to paclitaxel and some cells even become hypersensitive to paclitaxel. The reverse is also true of paclitaxel-resistant cell lines, which either show no change in resistance to cisplatin or have become hypersensitive to cisplatin. This inverse resistance relationship is also present between other platinum drugs such as carboplatin and the newer taxane docetaxel. The inverse resistance relationship was present in drug-resistant cell models developed with both platinums or taxanes as well as those developed with other classes of chemotherapeutics such as anthracyclines, topoisomerase inhibitors, anti-metabolites and even radiation. This suggested the involvement of cellular pathways that respond to a broad variety of drugs to produce either platinum resistance accompanied by taxane sensitivity or taxane resistance and platinum sensitivity.
The genetic modification of cell lines by over or under expressing genes can provide insight into which genes are involved in resistance to a given chemotherapeutic. These studies will often amplify or reduce the expression of a gene to a greater extent to what would be observed in the development of drug resistance in cancer patients but nevertheless provide insight into which pathways can mediate resistance. Transfection studies have linked the overexpression of copper efflux transporters ATP7A [5] and ATP7B [6] with cisplatin resistance. Decreasing the expression of DNA repair gene ERCC1 by siRNA [7] or glutathione transferase GSTP1 [8] by antisense has been shown to mediate sensitivity to cisplatin. Similarly, the overexpression of ABC transporter Pglycoprotein has been shown to mediate paclitaxel resistance [9] .
We undertook this systematic review to determine which genetic modifications in cell lines have created the inverse cisplatin/paclitaxel resistance phenotype. This will form a short list of genes which may play a role in the mechanism of the inverse resistance relationship as well as potential markers for monitoring the development of resistance in the clinical treatment of cancer.
METHODS
Medline was searched for cell lines which had been genetically modified and reported toxicity data for both cisplatin and paclitaxel. The following terms were used as Resistant cell models developed by selection with chemotherapy which have then been treated by transfection or antisense to reverse resistance were not included in the systematic review process, but were used when appropriate to strengthen the case for identified genes being involved in the inverse resistance phenotype. Cell lines which had multiple genetic modifications were excluded.
RESULTS AND DISCUSSION

Types of Genetic Modification
There are many experimental techniques to over or under express genes of interest to into the chromosome of the cell [10] . Adenovirus vectors can also be used to overexpress a gene of interest [11] . Transfection and adenoviruses can also be used to inhibit gene expression if they are used to introduce antisense oligonucleotides or generate small interfering RNAs (siRNA), described below. hybridizing to corresponding mRNA [12] . A ribozyme is an RNA molecule that can catalyse a chemical reaction. A Ribozyme catalytic centre is incorporated into antisense RNA and specifically cleaves and destroys the target RNA. This provides an advantage over standard antisense technology which only inactivates the target RNA without degrading it [13] . RNAi uses double-stranded RNAs (dsRNA) homologous to the gene being suppressed. Long dsRNAs are processed within the cell by dicer, a cellular ribonuclease III, to generate duplexes of about 21 nucleotides with 3'-overhangs known as small interfering RNAs (siRNAs) which mediate mRNA degradation [14] .
A gene can be knocked out from an animal in order to investigate the absence of a specific gene product. Gene knockout technology arose from the combination of two techniques: the culture of multipotent embryonic stem cells from mouse embryos and the induction of mutations into mammalian cells by homologous recombination. The embryonic stem cells could be isolated, manipulated in culture and then reintroduced into a wild type embryo. Knocking-in uses the same technique of homologous recombination as the knock-out strategy, but the targeting vector is designed to enhance the function of the gene of interest rather than disrupt it [15] . Fibroblasts from knockout or knock-in mice are often studied in culture for changes in resistance to chemotherapy agents.
Defining Resistance
When Studies which have developed cell lines from patients before and after chemotherapy have found that drug resistance in the clinic typically produces resistance of 2 to 3-fold [16, 17] . For the purposes of this review we have defined cross resistance between cisplatin and paclitaxel as greater than or equal to 2-fold resistance to both drugs. This definition is therefore based on what would be clinically observed as cross resistance.
We have defined cross sensitivity as less than or equal to 0.8-fold resistance to both drugs. (Figure 1 , indicated in black)
Alternatively, many studies will not report an IC 50 for their genetically modified cell lines. Rather, resistance or sensitivity will be defined by exposing the cell lines to a single dose of drug and then assaying for cell viability or level of apoptosis. We have reported the conclusions of the authors of these studies. Resistance was usually defined as a significant increase in viability or decrease in apoptosis after exposure to chemotherapy.
The literature search revealed 91 genetically modified cell lines which report toxicity or viability/apoptosis data for cisplatin and paclitaxel relative to their parental cell lines. There are three categories of the inverse cisplatin/paclitaxel resistance phenotype. Non-cross resistance is where the genetic modification has induced resistance to one drug with no change to the other compound. Hypersensitivity is resistance to one drug which has induced sensitivity to the other compound ( Figure 1 ).
Both these categories are likely to occur in the clinical treatment of cancer, where resistance develops to one compound but sensitivity is present to the other. The third category is non-cross sensitivity, where the genetic modification has produced sensitivity to one agent and not altered the toxicity of the other. This category is unlikely to occur in the clinic but genetic modifications which produce this category will aid in our understanding of the inverse resistance phenotype. The areas in Figure   1 shaded in grey are the categories of genetic modification that will aid our understanding of cisplatin resistance and paclitaxel sensitivity. The areas with grey stripes are the opposite phenotype, paclitaxel resistance and cisplatin sensitivity. Tables 1 and 2 summarise the genetically modified cell lines which correlate with the inverse cisplatin/paclitaxel resistance phenotype. Table 1 covers cisplatin resistance   and paclitaxel sensitivity and Table 2 covers paclitaxel resistance and cisplatin sensitivity. A total of 26 genes may therefore be associated with the inverse resistance phenotype. [20] Increase in cellular detoxification by dihydrodiol dehydrogenase (DDH) -cisplatin not direct substrate CH1 Ovarian ↑erbB2 Transfection 2.1 1.42 [23] Mechanism not investigated MCF-7 Breast ↑H-Ras Transfection 9.5 1.1 MCF-7
Genetic Modifications Which Induce the Inverse Cisplatin/Paclitaxel Phenotype
Breast ↑H-Ras Transfection 3.8 1 [24] Decrease in DNA fragmentation induced by cisplatin H460 NSCLC ↑MRIT/cFLIP Transfection Resistant No Change [25] Decreased Apoptosis in response to cisplatin, by blocking the activation of caspase-8 A2780 Ovarian ↑mutant p53 Transfection 2.5 1.1 [26] Mechanism not investigated SKBR-3 Breast ↓PKCε Antisense 2.7 1.1 [27] Decrease in DNA fragmentation induced by cisplatin Cisplatin No Change -Paclitaxel Sensitive A549 NSCLC ↓1kBa Adenovirus 1.625 0.183 [28] 1kBa Inhibits NFkB, Caspase-3 activity increased in response to paclitaxel Apoptosis MBR62 Breast ↑BRCA1 Transfection No change Sensitive [29] G2M arrest in response to paclitaxel, induction of GADD45 U-20S
Osteogenic Sarcoma ↑E2F-1 Transfection No change Sensitive [30] E2F-1(transcription factor) cyclin B1 levels and cdc2 kinase activity becoming sensitive to paclitaxel A549 Lung ↑HERG Transfection 0.875 0.039 [31] Potassium Channel, mechanism of paclitaxel sensitivity unknown SH-EP Neuroblastoma ↑MYCN Transfection 0.94 0.51 [32] Mechanism of paclitaxel sensitivity not studied [33] ↓BRCA1 leads to transcriptional modifications of the JNK pathway ↑JNK1 ↓JNK2 MCF-10A
Mammary Epithelial ↑c-erbB2 Transfection 0.625 3.5 [34] c-erbB2 is member of the EGFR family, mechanism of resistance/sensitivity unknown but likely due to alteration of growth or apoptotic pathways OAW42 Ovarian ↑Survivin Transfection 0.8 6.75 [35] Increased expression of anti-apoptotic survivin ↓Apoptosis Paclitaxel Resistant -Cisplatin No Change OVCAR3 Ovarian ↑Bcl-Xl Transfection No change Resistant [36] Increased expression of anti-apoptotic Bcl-Xl ↓Apoptosis SKOV3 Ovarian ↓HER-2 Ribozyme 1 79 [37] Cells with decreased HER-2 accumulate in S-phase (SKOV3 cells normally very high HER-2) OVCAR8 Ovarian ↑MAGE2 Transfection 1 4 OVCAR8 Ovarian ↑MAGE6 Transfection 1 4 [38] Increased Proliferation, No change in P-glycoprotein HeLa Ovarian ↑MRP1 Transfection 0.9 2 [39] MRP1 is a poor transporter of paclitaxel -low level resistance U-20S
Osteogenic Sarcoma ↑PGK1 Transfection 1 30 [40] Increase in Phosphoglycerate Kinase 1 possibly mediating increased glycolysis, no change in P-gp MCF-7
Breast ↑P-gp Transfection 1.2 36 [9] Increased P-glycoprotein-mediated efflux of Paclitaxel IGROV-1 Ovarian ↑Survivin Transfection 1.25 6.6 [35] Increased expression of anti-apoptotic survivin ↓Apoptosis Paclitaxel No Change -Cisplatin Sensitive OSE Ovarian (Mouse) ↓BRCA1 Knockout mouse Sensitive No Change [41] Increase in chromosome breaks and other abberations due to cisplatin Lymphocytes Lymphocytes (Human)
↓BRCA1
BRCA1 mutation
Sensitive No Change [42] Patients with BRCA mutation compared to healthy controls, mechanism not investigated H460 NSCLC ↑FHIT Adenovirus 0.57 1 [43] Fragile [45] Mechanism of Cisplatin sensitivity not investigated HeLa Ovarian ↑p53wt Adenovirus 0.68 0.93 [46] Increase in DNA fragmentation induced by cisplatin HFF Human Fibroblasts ↓RB E7 virus 0.53 0.93 [47] Mechanism of Cisplatin sensitivity not investigated MEF Mouse Fibroblasts ↓Xrcc2 Knockout mouse Sensitive No Change [48] Decrease in Homologous Recombination repair of DNA double strand breaks induced by cisplatin
From the literature review the gene which was correlated most highly with the inverse cisplatin/paclitaxel resistance phenotype was BRCA1 in six different studies [18, 19, 29, 33, 41, 42] . BRCA1 has been intensively investigated in many studies due to its role in familial breast and ovarian cancer, but has more recently been studied as a chemotherapy response marker in cell lines and in the clinic. When BRCA1 expression is increased this leads to cisplatin resistance and paclitaxel sensitivity [18, 19] . Conversely, when BRCA1 expression is decreased this leads to paclitaxel resistance and cisplatin sensitivity [33] . BRCA1 is the only gene identified which appears on both Tables 1 and 2 , showing that both increases and decreases in expression correlate with the inverse resistance phenotype. BRCA1's potential involvement with the inverse resistance mechanism will be discussed in detail later in this review article.
Increasing the expression of anti-apoptotic survivin has been shown to cause paclitaxel resistance in several studies [49] and no change or sensitivity to cisplatin in two ovarian cancer cell lines [35] . However, in studies which have only examined the toxicity of cisplatin and not paclitaxel, decreasing the expression of survivin caused cisplatin sensitivity and not resistance suggesting that survivin may not be involved in the inverse cisplatin/paclitaxel resistance phenotype [50, 51] .
Increased expression of dihydrodiol dehydrogenase (DDH) has caused cisplatin resistance and sensitivity to paclitaxel in a panel of cell lines including ovarian, cervical and lung cancers [20] . Increased DDH was thought to mediate cisplatin resistance by increasing the detoxification capability of the cell, although cisplatin is not a direct substrate of DDH. Increased expression of DDH has also been correlated with cisplatin resistance in ovarian cancer patients [52] . Decreasing the expression of DDH has been investigated, but the toxicity of cisplatin and paclitaxel were not examined [53] . However, the cells were rendered more sensitive to DNA binding drug bleomycin [53] . The role of DDH in the inverse resistance phenotype requires further study. Examining the toxicity of cisplatin and paclitaxel in cells with decreased DDH expression would be an important starting point.
Paclitaxel resistance can be mediated by P-glycoprotein export decreasing the cellular accumulation [3] . Surprisingly, the literature search only revealed one cellular model of increased paclitaxel resistance mediated by transfection of P-glycoprotein which also reported cisplatin toxicity data [9] . This is most likely due to two factors: 1)
Paclitaxel resistance mediated by P-glycoprotein is relatively easy to induce with paclitaxel treatment. 2) When P-glycoprotein has been transfected into cells cisplatin resistance may not have been examined as cisplatin is not a substrate of Pglycoprotein. However, we know from work in resistant cell models developed with paclitaxel treatment that P-glycoprotein is associated with the inverse cisplatin/paclitaxel resistance phenotype. Resistant cell models developed using paclitaxel in nasal septum [54] , osteosarcoma [55] and ovarian cancer cells [3, 56] have shown levels of paclitaxel resistance ranging from 8 to 1500-fold mediated by Pglycoprotein. There was no cross resistance to cisplatin in these cell models, many of which had become hypersensitive to cisplatin.
There are several limitations to the identification of genes involved in the inverse cisplatin/paclitaxel resistance mechanism by searching the literature. Studies which investigate resistance to cisplatin after genetic manipulations will often only examine cross resistance to other platinum agents, heavy metals or other DNA targeting chemotherapy [6, 7] . Similarly, studies investigating resistance to paclitaxel may only examine cross resistance to other microtubule targeting agents and or P-glycoprotein substrates and not cisplatin [57] . The other major limitation of this method is that it only examines genes which have already been identified, and the more popular the gene in terms of number of laboratories investigating it, the more likely it is to be examined in regards to both cisplatin and paclitaxel toxicities. Microarray-based studies designed to investigate the inverse resistance phenotype will no doubt reveal many other genes involved in the mechanism which have not been previously investigated.
Cisplatin/Paclitaxel Cross Resistance or Cross Sensitivity
The genetic modifications which have induced cisplatin/paclitaxel cross resistance or cross sensitivity are itemised in Table 3 . These genes are unlikely to be involved in [5] Increased in cisplatin efflux mediated by copper transporter. Paclitaxel resistance unexplained, no efflux or presence of P-gp A2780 Ovarian ↑Aurora-A Transfection Resistant Resistant [58] Aurora-A induces survival by activating Akt growth signalling C33A Cervical ↑BAG-1 Transfection Resistant Resistant [59] Increased expression of anti-apoptotic BAG-1 ↓Apoptosis A2780 Ovarian ↑Bcl-Xl Transfection Resistant Resistant [60] Increased expression of anti-apoptotic Bcl-Xl ↓Apoptosis HeLa Cervical ↓COX-2 siRNA Resistant Resistant [61] ↓Apoptosis in response to both cisplatin and paclitaxel [62] ↓Apoptosis in response to both cisplatin and paclitaxel
SKOV3
Ovarian ↓HtrA1 Antisense Resistant Resistant [63] Decreased expression of pro-apoptotic HtrA1 ↓Apoptosis EJ Bladder ↑p16 Adenovirus Resistant Resistant [64] Resistance mediated by growth arrest by replacement of functional p16 gene in p16 negative EJ cells HEC-1 Endometrial ↑PXR Transfection Resistant Resistant [65] ↓Apoptosis in response to both cisplatin and paclitaxel Cross Sensitivity A2780 Ovarian ↑Bax Adenovirus 0.18 0.48 OVCAR-3
Ovarian ↑Bax Adenovirus 0.17 0.17 [66] MNK45 Gastric ↑Bax Transfection 0.2 0.36 [67] Increased expression of pro-apoptotic Bax ↑Apoptosis MNK45 Gastric ↓Bcl-2 Antisense 0.34 0.28 [68] 8305C Thyroid ↓Bcl-2 Antisense Sensitive Sensitive [69] HUH6 Liver ↓Bcl-2 siRNA Sensitive Sensitive [70] Decreased expression of anti-apoptotic Bcl-2 ↑Apoptosis
Ovarian ↓Bcl-XL Antisense Sensitive Sensitive [36] Decreased expression of anti-apoptotic Bcl-Xl ↑Apoptosis H460 NSCLC ↓βIII Tubulin siRNA Sensitive Sensitive Calu-6 NSCLC ↓βIII Tubulin siRNA Sensitive Sensitive [71] ↑Apoptosis in response to both cisplatin and paclitaxel, altered microtubules and cell cycle in response to paclitaxel SKOV3ip1 Ovarian ↑E1A Adenovirus Sensitive Sensitive [72] ↑Apoptosis, Increased DNA fragmentation in response to paclitaxel MEFS Mice Fibroblasts ↓E2F4 Knockout Sensitive Sensitive [62] ↑Apoptosis in response to both cisplatin and pacliaxel 14 [73] Inhibition of growth factor Epidermal Growth Factor Receptor (EGFR) MNK45 Gastric ↑Gadd153 Transfection 0.18 0.69 [74] Possible pro-apoptotic gene MCF-10A
Mammary Epithelial ↑Ha-Ras Transfection 0.625 0.4375 [34] Oncogene, mechanism of sensitivity not investigated OV167 Ovarian ↑HtrA1 Adenovirus Sensitive Sensitive [63] Serine protease HtrA1, induces cell death and activates caspase3/7 Apoptosis CNE1 Nasopharygeal ↓Id-1 siRNA Sensitive Sensitive [75] Decreased expression of anti-apoptotic Id-1 ↑Apoptosis DU145 Prostate ↓IGF1R Antisense Sensitive Sensitive [76] Inhibition of growth factor type 1 insulin-like growth factor receptor OV167
Ovarian ↑MCJ Transfection 0.5 0.28 [77] MCJ member of DNAJ family, more sensitive to paclitaxel induced apoptosis SH-EP Neuroblastoma ↑MYCN Transfection Sensitive Sensitive [78] ↑Apoptosis in response to both cisplatin and paclitaxel HFF Human Fibroblasts ↓p53 E6 virus 0.13 0.12 [47] Cell cycle alteration in response to cisplatin treatment PC-3 Prostate ↓PDPK Fa Antisense Sensitive Sensitive [79] Proline-directed protein kinase FA, mechanism of sensitivity unknown HEC-1 Endometrial ↓PXR siRNA Sensitive Sensitive [65] ↑Apoptosis [80] Increased expression of pro-apoptotic p53 upregulated modulator of apoptosis (PUMA) Apoptosis U87-MG Glioma ↓hTR Antisense Sensitive Sensitive U373-MG Glioma ↓hTR Antisense Sensitive Sensitive [81] Decreased telomerase activity H460 NSCLC ↑TRAIL Adenovirus 0.1 0.006 [82] ↑Apoptosis in response to both cisplatin and paclitaxel -TRAIL (TNF-related apoptosis inducing ligand) T24 Bladder ↓TXAS siRNA 0.55 0.27 [83] Unknown TCC-SUP Bladder ↓TXAS siRNA 0.72 0.48 [83] Unknown the inverse cisplatin/paclitaxel resistance phenotype but may be useful in predicting cross resistance between cisplatin and paclitaxel. It is interesting to note which genes cause generalised resistance or sensitivity to two different classes of chemotherapy.
Some of these include well characterised apoptosis genes, decreased expression of anti-apoptotic Bcl-2 [68, 69] and Bcl-Xl [36] and increased expression of pro-apoptotic Bax [66, 67] all cause sensitivity to both cisplatin and paclitaxel. Similarly increased expression of Bcl-Xl by transfection produced cross resistance to cisplatin and paclitaxel [60] .
The overexpression of ATP7A by transfection produced cross resistance between cisplatin and paclitaxel which was unexpected [5] . Low-level resistance to cisplatin was mediated by ATP7As role as an efflux protein for platinum [84] . The resistance to paclitaxel was higher and ranged from 14 to 325 -fold resistance. The mechanism of this resistance remains unexplained, but was not mediated by increased expression of P-glycoprotein or increased efflux of paclitaxel from the cell by any other transporter.
Role of BRCA1 in the Inverse Cisplatin/Paclitaxel Resistance Phenotype
Our systematic review of the literature found that when BRCA1 expression is increased cisplatin resistance and paclitaxel sensitivity occurs [18, 19] and, conversely, when BRCA1 expression is decreased this leads to paclitaxel resistance and cisplatin sensitivity occurs [33] . BRCA1's role in the mechanism of cisplatin or paclitaxel resistance was the subject of a recent review article by Mullen et al 2006 in
Biochimica and Biophysica Acta [85] so here we will only cover the main pathways influenced by BRCA1 (Figure 2 ), DNA repair and apoptosis, rather than a complete review of all the genes BRCA1 has been shown to regulate.
In cisplatin-resistant MCF-7 breast cancer cells BRCA1 up-regulation is associated with DNA repair mediated resistance to cisplatin [86] . Antisense inhibition of BRCA1 in this same cisplatin-resistant model resulted in an increased sensitivity to cisplatin, a decreased proficiency of DNA repair and an enhanced rate of apoptosis. BRCA1 has been found to be required for the subnuclear assembly of homologous recombination repair protein RAD51 into foci at the site of DNA double-strand breaks due to cisplatin [87, 88] . BRCA1 deficiency confers resistance to paclitaxel and has been associated with a defective apoptotic response in BRCA1-deficient cells, suggesting that BRCA1 could regulate apoptotic pathways [19] (Figure 2 ). BRCA1 deficiency has also been shown to mediate paclitaxel resistance through premature inactivation of the spindle checkpoint at the metaphase anaphase transition [89] and through alterations of the JNK signalling pathway [33] .
There may be an overall inverse resistance relationship between DNA targeting chemotherapy and microtubule targeting chemotherapy in which BRCA1 participates.
Increased BRCA1 expression by transfection in HCC1937 breast cancer cells leads to increased resistance to DNA damaging agents etoposide and bleomycin as well as cisplatin [19] . Sensitivity to vinorelbine was also associated with increased BRCA1 expression along with paclitaxel [19] .
Clinical Role for BRCA1 in Predicting Treatment Outcomes
BRCA1 is an important genetic factor in hereditary breast and ovarian cancer and there is increasing evidence of an important role for BRCA1 in the sporadic forms of both cancer types [85] . Therefore we sought to determine if BRCA1 mutations or alterations in BRCA1 mRNA and protein expression influence the response to cisplatin or paclitaxel-based chemotherapy.
Cisplatin combination chemotherapy is the cornerstone of treatment of ovarian carcinomas. Initial platinum responsiveness in ovarian cancer is high, but up to 80% of patients will eventually relapse and become cisplatin resistant [90] . Ovarian cancer patients with BRCA1 mutations have a higher 5-year survival rate (78.6%) compared to sporadic ovarian cancer (30.3%) [91] . All patients in this study were treated with at least 2 courses of cisplatin-based chemotherapy after surgery. This correlates with the in vitro data, as a decrease in BRCA1 should promote sensitivity to cisplatin.
However, when the response rate of the first-line cisplatin chemotherapy regimen is examined the total of complete and partial responses is the same between patients with a BRCA1 mutation and that of sporadic ovarian cancer. The ratio of complete to partial responses was slightly higher in the BRCA1 mutation cohort but due to the small number of patients (7) it is unclear if this difference caused the large difference in survival 5 years later. Other studies have also found increased survival of BRCA1
ovarian cancer patients over a five year period who have been treated with cisplatinbased therapy [92, 93] . However, it is difficult to determine if the choice of cisplatinbased chemotherapy at first line is causing the dramatic difference in outcome 5 years later as the salvage chemotherapy treatments given to the BRCA1 patients are often not recorded. Complicating this further is the fact that paclitaxel is often given as salvage therapy in ovarian cancer or combined with cisplatin in first-line therapy [1] and BRCA1 mutation patients should be less responsive to paclitaxel therapy.
BRCA1 mRNA and protein expression levels have also been examined in tumours and compared to response to chemotherapy and 5-year survival. Low BRCA1 mRNA levels correlated with increased response to cisplatin/gemcitabine chemotherapy and increased 5-year survival in a group of 55 non-small cell lung cancer patients [94] . This again correlates with the in vitro data, as a decrease in BRCA1 should promote sensitivity to cisplatin. Low BRCA1 protein expression has also been shown to correlate with a shorter time to progression after taxane-based chemotherapy in breast cancer [95] . This also correlates with the in vitro data, as a decrease in BRCA1 should promote resistance to taxanes such as paclitaxel. However, there was no decrease in response to taxane-based chemotherapy in these patients, just a shorter time to progression [95] . Decreased levels of BRCA1 protein have also been shown to correlate with improved 5-year survival in breast cancer to other treatment regimens such as surgery and adjuvant radiotherapy [96] and combination treatment with cyclophosphamide, epirubicin and 5-fluorouracil [97] .
CONCLUSIONS
BRCA1 is not the only gene responsible for the inverse cisplatin/paclitaxel resistance phenotype. BRCA1 may be over represented in the literature because of the interest in this gene in hereditary cancers. However, due to the large body of literature on BRCA1 we propose that it could be the first of a panel of cellular markers to predict the inverse cisplatin/paclitaxel resistance phenotype. BRCA1 mRNA or protein expression levels need to be further examined in tumour banks and correlated with both response to first and second line chemotherapy as well as time to progression and 5-year survival in order to fully understand the role of this protein in the inverse cisplatin/paclitaxel resistance phenotype.
